Related Experiment Video
Updated: Aug 14, 2026
Murine Model of CD40-activation of B cells
Published on: March 6, 2010
Primary cutaneous CD30 (Ki-1)-positive non-anaplastic B-cell lymphoma
Enrique Herrera1, María Gallardo, Ricardo Bosch
1Department of Dermatology, University Hospital, School of Medicine, Málaga, Spain. dermafac@ccuma.sci.uma.es
Insights
This case study highlights a rare CD30-positive B-cell lymphoma on the scalp. The non-anaplastic diffuse lymphoma showed a positive response to chemotherapy.
Area of Science:
- Hematology
- Oncology
- Dermatopathology
Background:
- CD30 (Ki-1)-positive lymphoproliferative disorders typically involve T-cells.
- B-cell origin CD30-positive lymphoproliferative disorders are exceptionally rare.
- Understanding rare B-cell lymphomas is crucial for accurate diagnosis and treatment.
Observation:
- A 51-year-old male presented with a large, lobulated scalp tumor.
- Histopathology revealed medium and large non-anaplastic lymphocytes with a B-cell phenotype (CD20+, CD3-).
- Tumor cells were positive for CD30 (Ki-1).
Findings:
- The scalp tumor was diagnosed as a diffuse B-cell lymphoma.
- The lymphoma exhibited an unusual non-anaplastic morphology with CD30 (Ki-1) positivity.
- The patient achieved remission after CHOP protocol chemotherapy.
Implications:
- This case expands the spectrum of CD30-positive lymphomas.
- Highlights the importance of immunophenotyping in diagnosing rare B-cell malignancies.
- Suggests that CD30-positive B-cell lymphomas may respond to standard chemotherapy regimens.
Background:
The CD30 (Ki-1)-positive lymphoproliferative disorders show a non-epidermotropic infiltrate of large-sized pleomorphic T cells, being extremely rare those that develop from B cells.
Clinical Case:
A 51-year-old white man presented with a 8x10 cm lobulated scalp tumor that had developed during the previous 8 months. Histopathology demonstrated a proliferation of medium and large-sized non-anaplasic lymphocytes. The tumor cells (CD45+) expressed B phenotype (CD20+, CD3) and were CD30 (Ki-1) positive. The extension study revealed no extracutaneous involvement and the lesion resolved following chemotherapy. Two years later, after six cycles of chemotherapy that followed the CHOP protocol the patient remained asymptomatic.
Conclusions:
We report a patient with a diffuse lymphoma of medium and large-sized B phenotype cells on the scalp that showed the unusual characteristic of being both non-anaplastic and CD30 (Ki-1) positive.
